BR0111948A - Composição para entrega de fator de crescimento hematopoiético - Google Patents
Composição para entrega de fator de crescimento hematopoiéticoInfo
- Publication number
- BR0111948A BR0111948A BR0111948-6A BR0111948A BR0111948A BR 0111948 A BR0111948 A BR 0111948A BR 0111948 A BR0111948 A BR 0111948A BR 0111948 A BR0111948 A BR 0111948A
- Authority
- BR
- Brazil
- Prior art keywords
- growth factor
- composition
- biocompatible polymer
- hematopoietic growth
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"COMPOSIçãO PARA ENTREGA DE FATOR DE CRESCIMENTO HEMATOPOIéTICO." Uma composição para administração de fator de crescimento hematopoiético inclui um fator de crescimento hematopoiético, um veículo líquido, um primeiro polímero biocompatível e um segundo polímero biocompatível. A composição apresenta comportamento de viscosidade térmico inverso devido à interação entre o primeiro polímero biocompatível e o veículo líquido. O segundo polímero biocompatível auxilia a proteger o primeiro polímero biocompatível de ser dissolvido in vivo, seguindo a administração a um hospedeiro.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21429800P | 2000-06-26 | 2000-06-26 | |
US27489101P | 2001-03-09 | 2001-03-09 | |
PCT/US2001/020486 WO2002000171A2 (en) | 2000-06-26 | 2001-06-26 | Composition for delivery of hematopoietic growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111948A true BR0111948A (pt) | 2004-08-24 |
Family
ID=26908857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111948-6A BR0111948A (pt) | 2000-06-26 | 2001-06-26 | Composição para entrega de fator de crescimento hematopoiético |
Country Status (6)
Country | Link |
---|---|
US (6) | US6649189B2 (pt) |
EP (1) | EP1351696A4 (pt) |
AU (2) | AU2001273034A1 (pt) |
BR (1) | BR0111948A (pt) |
MX (1) | MXPA03000190A (pt) |
WO (2) | WO2002000173A2 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361330B2 (en) * | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
AU2001276831A1 (en) * | 2000-06-22 | 2002-01-02 | Rxkinetix, Inc. | Delivery vehicle composition and methods for delivering antigens and other drugs |
AU2001273034A1 (en) * | 2000-06-26 | 2002-01-08 | Rxkinetix, Inc. | Composition for delivery of hematopoietic growth factor |
US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
CN1604788B (zh) * | 2001-10-16 | 2013-04-17 | 里克斯金蒂克斯公司 | 高浓度蛋白制剂及其制备方法 |
US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
SI21258A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol |
US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
US8821473B2 (en) | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US7641643B2 (en) * | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US8071580B2 (en) * | 2004-10-01 | 2011-12-06 | Prometic Biosciences Inc. | Medium-chain length fatty alcohols as stimulators of hematopoiesis |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US8828433B2 (en) * | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
CA2615122A1 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
US7732190B2 (en) | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
EP2482828B1 (en) | 2009-10-02 | 2014-12-17 | Baxter International Inc | Hematopoietic stem cells for use in the treatment of a kidney injury |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US20130216495A1 (en) | 2012-02-21 | 2013-08-22 | Baxter Healthcare Sa | Pharmaceutical composition comprising cd34+ cells |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US10052283B2 (en) * | 2014-02-20 | 2018-08-21 | Gwangju Institute Of Science And Technology | Composition for forming pluronic-based hydrogel with improved stability |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
JP2024511064A (ja) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | 細胞捕獲及び増殖 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033584T2 (de) * | 1989-10-16 | 2001-03-08 | Amgen Inc., Thousand Oaks | Stammzellenfaktor |
US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
EP0551626A1 (en) | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
EP0766741A4 (en) * | 1994-07-07 | 1998-02-25 | Immunex Corp | GM-CSF CONTAINED FUSION PROTEINS AND ANTIGENS AND THEIR EXPRESSION IN YEAST |
US5840338A (en) * | 1994-07-18 | 1998-11-24 | Roos; Eric J. | Loading of biologically active solutes into polymer gels |
US5939485A (en) * | 1995-06-19 | 1999-08-17 | Medlogic Global Corporation | Responsive polymer networks and methods of their use |
US5728581A (en) | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5902110A (en) * | 1995-12-18 | 1999-05-11 | The Block Drug Company | Bone regeneration |
US6017527A (en) | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
US5861174A (en) * | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US6054315A (en) * | 1997-09-05 | 2000-04-25 | The Board Of Regents Of The University Of Oklahoma | Method for making activated neutrophils recognizable to macrophages |
US6004573A (en) * | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6238888B1 (en) * | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
GB9801061D0 (en) | 1998-01-20 | 1998-03-18 | Univ Nottingham | Patterning technique |
CA2305787A1 (en) * | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
US6280742B1 (en) | 1998-06-17 | 2001-08-28 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
JP2002531217A (ja) | 1998-12-04 | 2002-09-24 | チャンドラシェカー ピー. パサック, | 生体適合性架橋ポリマー |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
EP1163001A2 (en) | 1999-03-24 | 2001-12-19 | The Secretary of State for Defence | Vaccine composition |
AU3879200A (en) | 1999-08-16 | 2001-03-13 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
AU2001273034A1 (en) * | 2000-06-26 | 2002-01-08 | Rxkinetix, Inc. | Composition for delivery of hematopoietic growth factor |
-
2001
- 2001-06-26 AU AU2001273034A patent/AU2001273034A1/en not_active Abandoned
- 2001-06-26 US US09/893,372 patent/US6649189B2/en not_active Expired - Lifetime
- 2001-06-26 WO PCT/US2001/020544 patent/WO2002000173A2/en active Application Filing
- 2001-06-26 EP EP01952261A patent/EP1351696A4/en not_active Withdrawn
- 2001-06-26 WO PCT/US2001/020486 patent/WO2002000171A2/en active Search and Examination
- 2001-06-26 MX MXPA03000190A patent/MXPA03000190A/es active IP Right Grant
- 2001-06-26 AU AU2001273041A patent/AU2001273041A1/en not_active Abandoned
- 2001-06-26 US US09/893,339 patent/US6875441B2/en not_active Expired - Fee Related
- 2001-06-26 BR BR0111948-6A patent/BR0111948A/pt not_active IP Right Cessation
-
2005
- 2005-03-04 US US11/073,153 patent/US20050147682A1/en not_active Abandoned
- 2005-03-04 US US11/073,253 patent/US20050147684A1/en not_active Abandoned
- 2005-03-04 US US11/073,240 patent/US20050147683A1/en not_active Abandoned
-
2008
- 2008-11-06 US US12/291,344 patent/US20090232835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090232835A1 (en) | 2009-09-17 |
MXPA03000190A (es) | 2004-09-13 |
WO2002000173A3 (en) | 2002-06-13 |
EP1351696A2 (en) | 2003-10-15 |
US6649189B2 (en) | 2003-11-18 |
AU2001273034A1 (en) | 2002-01-08 |
WO2002000171A3 (en) | 2003-07-17 |
EP1351696A4 (en) | 2004-04-14 |
US20050147682A1 (en) | 2005-07-07 |
AU2001273041A1 (en) | 2002-01-08 |
US20050147684A1 (en) | 2005-07-07 |
US20020102272A1 (en) | 2002-08-01 |
WO2002000173A2 (en) | 2002-01-03 |
US20020028515A1 (en) | 2002-03-07 |
US20050147683A1 (en) | 2005-07-07 |
WO2002000171A2 (en) | 2002-01-03 |
US6875441B2 (en) | 2005-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111948A (pt) | Composição para entrega de fator de crescimento hematopoiético | |
AR019114A1 (es) | Nuevas microesferas a base de poli(metiliden malonato), su procedimiento de preparacion y composiciones farmaceuticas que las contienen | |
BR9907832A (pt) | Composição de propofol contendo sulfito | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
DE69412250D1 (de) | Pyridobismidazole enthaltendes rigid-rod-Polymer | |
CO5670348A2 (es) | Sistema hidrofobo para blanquear los dientes y metodos de uso | |
DE69310518D1 (de) | Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält | |
MA25681A1 (fr) | Systeme d'administration de compositions orales de soins comprenant une resine d'organosiloxane utilisant une bandelette de soutien amovible. | |
ES2068715T3 (es) | Utilizacion de nanopigmentos de oxidos metalicos para proteger la queratina de los cabellos contra las agresiones atmosfericas, principalmente la luz, procedimiento de proteccion de los cabellos, y composicion gelificada que utiliza estos nanopigmentos. | |
BR0209896A (pt) | Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo | |
RU94043772A (ru) | Пропинил-диароматические соединения, фармацевтические и косметические составы на их основе | |
DE59208091D1 (de) | Alkenylgruppen aufweisende Siloxancopolymere, deren Herstellung und Verwendung | |
BRPI0502578A (pt) | composições contendo agentes antiacne e uso das mesmas | |
ATE257014T1 (de) | Lichtbilderzeugungskontrastmitteln | |
DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
ES2042462T1 (es) | Producto para el tratamiento del cabello en forma de una microemulsion. | |
RU2002109814A (ru) | Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами | |
AR007649A1 (es) | Composicion de relleno para forma de dosis farmaceutica de gelatina blanda y forma de dosis farmaceutica que la comprende | |
DE60126433D1 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
BR0011030A (pt) | Composições de cicloporina substancialmente livre de óleo | |
ATE221059T1 (de) | Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend | |
AR021370A1 (es) | Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides | |
ES2160163T3 (es) | Composiciones farmaceuticas a base de derivados de la clase de los taxanos. | |
HUP0201830A2 (en) | Compositions comprising organosiloxane resins for delivering oral care substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 35/14 , A61K 38/00 , A61K 38/16 , C07K 14/00 , C07K 1/00 , C07K 16/00 , C07K 17/00 , A01N 37/18 Ipc: A61K 38/16 (2006.01) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |